BioCentury
ARTICLE | Financial News

BioMimetic gains on FDA update

March 28, 2008 11:21 PM UTC

BioMimetic (NASDAQ:BMTI) added $1.95 (30%) to $8.45 on Friday after the company said it did not receive any communication from FDA regarding its recombinant human platelet-derived growth factor (rhPDGF) products. On Thursday, BioMimetic fell $8.24 (56%) to $6.50 after FDA said it is conducting a safety review of Regranex becaplermin gel, a PDGF product from Johnson & Johnson (NYSE:JNJ), based on data suggesting there may be an increased risk of death from cancer in patients receiving the diabetic foot ulcer product (See BioCentury Extra, Thursday, March 27, 2008). ...